Wall Street brokerages expect Quanterix Co. (NASDAQ:QTRX) to announce ($0.32) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Quanterix’s earnings, with estimates ranging from ($0.35) to ($0.29). Quanterix posted earnings of ($0.39) per share during the same quarter last year, which would suggest a positive year over year growth rate of 17.9%. The firm is expected to report its next earnings report after the market closes on Wednesday, May 5th.
According to Zacks, analysts expect that Quanterix will report full-year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.23) to ($1.01). For the next fiscal year, analysts forecast that the company will report earnings of ($0.76) per share, with EPS estimates ranging from ($1.12) to ($0.40). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Quanterix.
Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, March 1st. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The business had revenue of $26.13 million for the quarter, compared to analyst estimates of $25.35 million. Quanterix had a negative net margin of 41.69% and a negative return on equity of 22.37%.
QTRX has been the subject of several research reports. Zacks Investment Research upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a research note on Wednesday, March 31st. SVB Leerink lifted their price objective on shares of Quanterix from $75.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 9th. Finally, Canaccord Genuity lifted their price objective on shares of Quanterix from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, March 3rd.
In related news, SVP David C. Duffy sold 1,667 shares of the business’s stock in a transaction on Friday, March 19th. The shares were sold at an average price of $58.36, for a total value of $97,286.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO E Kevin Hrusovsky sold 3,432 shares of the business’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $62.52, for a total transaction of $214,568.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,483 shares of company stock valued at $1,385,718. 25.40% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. HM Payson & Co. purchased a new stake in shares of Quanterix in the third quarter valued at about $44,000. Nisa Investment Advisors LLC raised its holdings in shares of Quanterix by 19.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,250 shares of the company’s stock valued at $58,000 after buying an additional 200 shares during the last quarter. Strs Ohio purchased a new stake in shares of Quanterix in the third quarter valued at about $158,000. Pathway Capital Management LP purchased a new stake in shares of Quanterix in the fourth quarter valued at about $200,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Quanterix by 30.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,485 shares of the company’s stock valued at $204,000 after buying an additional 815 shares during the last quarter. 71.60% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:QTRX traded down $4.41 during trading on Tuesday, hitting $52.31. The company’s stock had a trading volume of 431,867 shares, compared to its average volume of 416,914. The business has a 50 day moving average price of $60.37 and a two-hundred day moving average price of $57.89. The company has a market capitalization of $1.90 billion, a PE ratio of -46.29 and a beta of 1.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.18 and a current ratio of 7.65. Quanterix has a fifty-two week low of $23.87 and a fifty-two week high of $92.57.
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Further Reading: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.